Company intelligence / Profile preview

UBS O'Connor

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

UBS O'Connor is a multi-strategy hedge fund manager that was part of UBS Asset Management, specializing in relative value, event-driven, private credit, and commodities strategies. It managed approximately $11 billion in assets and operated globally. While it established a healthcare-focused investment team, it is not itself a therapeutics or biotech R&D company. The firm is in the process of being acquired by Cantor Fitzgerald.

Industry: Investors

Partnerships

Cantor Fitzgerald (acquirer, commercial arrangement post-acquisition)

Beyond the preview

Go deeper on UBS O'Connor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBS O'Connor.

Explore the full profile